Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Carney

Showing results (271-280 of 336) with videos related to

Pageof 34
Sort By:
JAMA Oncology|December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical TrialDebra L Richardson, Michael W Sill, Robert L Coleman, et al.
International Journal of Cancer|May 18, 2010
Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association ConsortiumGalina Lurie, Lynne R Wilkens, Pamela J Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2020
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)David S Miller, Virginia L Filiaci, Robert S Mannel, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 14, 2013
Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controlsKathryn L Terry, Stalo Karageorgi, Yurii B Shvetsov, et al.
Nature Medicine|August 15, 2017
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitorsHana Janouskova, Geniver El Tekle, Elisa Bellini, et al.
Cancer Science|December 17, 2017
Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association ConsortiumTomotaka Ugai, Linda E Kelemen, Mika Mizuno, et al.
BMC Cancer|January 24, 2013
Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association ConsortiumLinda E Kelemen, Elisa V Bandera, Kathryn L Terry, et al.
Epidemiology (Cambridge, Mass.)|February 7, 2020
Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship ExploredAlice W Lee, Anna H Wu, Ashley Wiensch, et al.
Plos One|February 25, 2011
The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white womenGalina Lurie, Mia M Gaudet, Amanda B Spurdle, et al.
Journal of the National Cancer Institute|July 12, 2023
A framework for assessing interactions for risk stratification models: the example of ovarian cancerMinh Tung Phung, Alice W Lee, Karen McLean, et al.
Pageof 34

Showing results (271-280 of 336) with videos related to

Sort By:
Pageof 34
JAMA Oncology|December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical TrialDebra L Richardson, Michael W Sill, Robert L Coleman, et al.
International Journal of Cancer|May 18, 2010
Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association ConsortiumGalina Lurie, Lynne R Wilkens, Pamela J Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2020
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)David S Miller, Virginia L Filiaci, Robert S Mannel, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 14, 2013
Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controlsKathryn L Terry, Stalo Karageorgi, Yurii B Shvetsov, et al.
Nature Medicine|August 15, 2017
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitorsHana Janouskova, Geniver El Tekle, Elisa Bellini, et al.
Cancer Science|December 17, 2017
Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association ConsortiumTomotaka Ugai, Linda E Kelemen, Mika Mizuno, et al.
BMC Cancer|January 24, 2013
Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association ConsortiumLinda E Kelemen, Elisa V Bandera, Kathryn L Terry, et al.
Epidemiology (Cambridge, Mass.)|February 7, 2020
Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship ExploredAlice W Lee, Anna H Wu, Ashley Wiensch, et al.
Plos One|February 25, 2011
The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white womenGalina Lurie, Mia M Gaudet, Amanda B Spurdle, et al.
Journal of the National Cancer Institute|July 12, 2023
A framework for assessing interactions for risk stratification models: the example of ovarian cancerMinh Tung Phung, Alice W Lee, Karen McLean, et al.
Pageof 34